WEBULL
News
TRSBF
3.900
NaN%
--
3SBio Announces Strategic Share Placement to Raise HK$3 Billion
TipRanks · 3d ago
Guotai Haitong Remains a Buy on 3SBio (TRSBF)
TipRanks · 5d ago
Citic Securities Remains a Buy on 3SBio (TRSBF)
TipRanks · 6d ago
BOCOM International Holdings Company Sticks to Its Buy Rating for 3SBio (TRSBF)
TipRanks · 11/28 05:05
Analysts Are Bullish on These Healthcare Stocks: Fisher & Paykel Healthcare Corporation Limited (FSPKF), 3SBio (TRSBF)
TipRanks · 11/26 00:30
3SBio Announces Proposed Spin-Off and Listing of Mandi Inc.
TipRanks · 11/20 14:41
Huatai Securities Remains a Buy on 3SBio (TRSBF)
TipRanks · 11/06 05:07
3SBio Subsidiary Mandi Inc. Issues Shares Under Equity Incentive Plan
TipRanks · 10/20 12:37
UBS Sticks to Its Buy Rating for 3SBio (TRSBF)
TipRanks · 09/29 15:15
Weekly Report: what happened at TRSBF last week (0908-0912)?
Weekly Report · 09/15 11:05
Weekly Report: what happened at TRSBF last week (0901-0905)?
Weekly Report · 09/08 11:07
3SBio’s Strategic Alliance with Pfizer and Promising Growth Potential Justify Buy Rating
TipRanks · 09/05 10:15
3SBio’s Promising Future: Buy Rating Backed by Financial Gains and Innovative Drug Pipeline
TipRanks · 09/04 05:55
Goldman Sachs Keeps Their Hold Rating on 3SBio (TRSBF)
TipRanks · 09/02 17:05
CLSA Sticks to Its Buy Rating for 3SBio (TRSBF)
TipRanks · 09/02 13:25
Weekly Report: what happened at TRSBF last week (0825-0829)?
Weekly Report · 09/01 11:02
3SBio, Inc. Reports Strong Net Profit Growth
TipRanks · 08/30 03:54
3SBio Reports Increased Profits Despite Revenue Dip in H1 2025
TipRanks · 08/29 10:10
Weekly Report: what happened at TRSBF last week (0818-0822)?
Weekly Report · 08/25 11:12
3SBio Inc. Schedules Board Meeting to Review Interim Results and Dividend
TipRanks · 08/19 08:50
More
Webull provides a variety of real-time TRSBF stock news. You can receive the latest news about 3Sbio through multiple platforms. This information may help you make smarter investment decisions.
About TRSBF
3SBio Inc is an investment holding company principally engaged in the development, production, marketing and sale of biopharmaceutical products. The Company's main products include biopharmaceuticals such as TPIAO, EPIAO, Yisaipu, and Cipterbin, as well as small moleculessuch as Mandi and Remitch. The Company is also engaged in the contract development and manufacturing operations (CDMO) business that provides customers with research, development and production of a variety of biopharmaceuticals and therapeutic technology platform services. The Company's products are mainly used for chemotherapy-induced thrombocytopenia (CIT), anemia caused by chronic kidney disease (CKD), treatment of chemotherapy-induced anemia (CIA), ankylosing spondylitis (AS) and psoriasis. The Company mainly operates its businesses in the domestic and overseas markets.